Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.55% Nasdaq Up0.29%

Celgene Corporation (CELG)

-NasdaqGS
139.84 Apr 15, 4:00PM EDT
|Pre-Market : 141.00 Up 1.16 (0.83%) 8:53AM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
United States - Map
Phone: 908-673-9000
Fax: 908-673-9001
Website: http://www.celgene.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:5,100

Business Summary 

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders; and strategic alliance with Forma Therapeutics. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Celgene Corporation

Corporate Governance 
Celgene Corporation’s ISS Governance QuickScore as of Apr 1, 2014 is 4. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 1; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Robert J. Hugin MBA, 59
Chairman, Chief Exec. Officer, Pres and Chairman of Exec. Committee
4.58M1.10M
Ms. Jacqualyn A. Fouse Ph.D., 53
Chief Financial Officer, Chief Accounting Officer and Exec. VP
1.25M0.00
Mr. Perry A. Karsen , 59
Chief Operations Officer, Exec. VP and Chief Exec. Officer of Celgene Cellular Therapeutics
1.87M0.00
Dr. Thomas O. Daniel M.D., 60
Exec. VP and Pres of Research & Early Devel.
1.58M0.00
Mr. Mark J. Alles , 55
Chief Commercial Officer, Global Head of Hematology & Oncology and Exec. VP
1.43M0.00
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders